BPGbio’s Interrogative Biology® platform has already advanced a robust pipeline of late-stage drug candidates and R&D assets in oncology, neurology and rare diseases. We maintain our strong focus on diseases that represent an unmet need in medicine.
Through our strategic global network of hospitals and academic medical centers, BPGbio continues to add diversity and depth to a 100,000+ sample rich biobank leading to more discoveries. We continue to strengthen our pipeline while improving research outcomes with lower incremental costs for patients and healthcare systems around the world.
